TSHA

Taysha Gene Therapies, Inc. [TSHA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TSHA Stock Summary

Top 10 Correlated ETFs

TSHA

Top 10 Correlated Stocks

TSHA

In the News

TSHA Financial details

Company Rating
-
Market Cap
549.83M
Income
-114M
Revenue
15.45M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
52
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.1
Forward P/E
-
PEG
0.17
P/S
25.02
P/B
-4.91
P/C
-
P/FCF
-6.87
Quick Ratio
0.91
Current Ratio
0.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.37
EPS next Y
-
EPS next Q
-
EPS this Y
-75.13%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-24.06%
EPS Q/Q
-127.96%
-
-
-
-
SMA20
-28.32%
SMA50
-21.52%
SMA100
-44.14%
Inst Own
-
Inst Trans
-
ROA
-112%
ROE
877%
ROC
-7.27%
Gross Margin
100%
Oper. Margin
-776%
Profit Margin
-1532%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.5-3.89
52W High
-
52W Low
-
RSI
51.66
Rel Volume
1.68
Avg Volume
2.77M
Volume
4.66M
Perf Week
20.83%
Perf Month
-17.14%
Perf Quarter
-26.4%
Perf Half Y
-28.22%
-
-
-
-
Beta
0.262
-
-
Volatility
0.09%, 0.26%
Prev Close
16.94%
Price
1.45
Change
21.85%

Something similar

Top by Market Cap
VTI
BRK-A
AAPL
LLY.DE
ABEC.DE
Top Correlated ETFs
UYLD
XBI
LABU
INR.DE
BBC
Top Correlated Stocks
BRNL.AS
MAU.PA
PCVX
1193.HK
1525.HK
Similar Market Cap
BBGI.L
MYD
MPE.L
GTLIX
0536.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 2.77M
  • Market Capitalization 549.83M
  • Employee 52
  • CEO Mr. Sean P. Nolan
  • Headquarters Dallas,TX,US
  • IPO Date 2020-09-24
  • Website https://www.tayshagtx.com

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.